Navigation Links
Anesiva Announces New Zingo Marketing and Distribution Agreement
Date:4/29/2008

SOUTH SAN FRANCISCO, Calif., April 29 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced a new exclusive Zingo(TM) marketing and distribution agreement, with Green Vision Company, for several Middle Eastern countries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is approved in the U.S. to provide topical local analgesia prior to peripheral IV insertions or blood draws in children three to 18 years of age.

Green Vision is a pharmaceutical company headquartered in Qatar. The agreement covers Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia and United Arab Emirates. Green Vision will be responsible for obtaining and maintaining product registrations in the licensed territories, as well as sales and marketing in the region. Terms of the agreement include an upfront payment, regulatory and sales milestones and royalty payments.

"This agreement further extends the potential markets for Zingo, a needle-free, local analgesic with a rapid onset of action, prior to peripheral venous access procedures in children, and is further validation of the unmet need Zingo addresses," said John P. McLaughlin, Anesiva's chief executive officer.

About Zingo(TM)

Zingo(TM) is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local anesthesia to reduce the pain associated with peripheral IV insertions or blood draws. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. Zingo is approved in the U.S. to reduce the pain associated with peripheral IV insertions or blood draws in children three to 18 years of age. In clinical trials, the
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
2. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
3. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
4. Anesiva Appoints Daniel Janney to Board of Directors
5. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
6. Anesiva Announces Completion of Common Stock Offering
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... According to a new market research report ... and Joint) Market (By Technology - Stem Cell ... Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic ... Share, Growth, Trends and Forecast, 2013 - 2019" ... was valued at USD 2.6 billion in 2012 ...
(Date:7/28/2014)... YORK , July 28, 2014  David ... ConvergeHEALTH by Deloitte , has been elected ... Interchange Standards Consortium, a non-profit working to establish ... data, particularly as it relates to electronic health ... continue CDISC,s mission of collaborating with organizations across ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... July 26, 2014 Canada Endoscopy ... market data on the Canada Endoscopy Visualization Systems ... US dollars, volume (in units) and average prices ... Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems and ... at http://www.marketresearchreports.biz/analysis/213254 . , The report also ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5
... researchers have identified a gene that is specifically responsible ... lead to stem cell therapies to treat brain injuries ... Edwin Monuki, doctoral student Karla Hirokawa and their colleagues ... Developmental & Cell Biology found that a gene called ...
... Jan. 17 NEXCORE Technology,Inc, a world-class original ... the intellectual property rights for the,development of a ... new system provides significantly greater control over the,inflow/outflow ... on the system are held by Drs. Atul ...
... Program Under Development to Improve Outcomes of Coronary ... Grafting (CABG) and Cardiac Valve Surgeries, VANCOUVER, ... -,Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... that they have entered into an,exclusive licensing agreement ...
Cached Biology Technology:Discovery of 'creator' gene for cerebral cortex points to potential stem cell treatments 2NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System 2Angiotech and Symphony Medical Announce Licensing Agreement 2Angiotech and Symphony Medical Announce Licensing Agreement 3Angiotech and Symphony Medical Announce Licensing Agreement 4Angiotech and Symphony Medical Announce Licensing Agreement 5Angiotech and Symphony Medical Announce Licensing Agreement 6
(Date:7/28/2014)... suggest two ways to effectively address the problem that birth ... compared to women of a normal body mass index. , ... as the population has increased in weight, concern has grown ... have consistently found that obesity has a negative impact on ... how well the pill prevents pregnancy. , "Birth ...
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are ... of varying flexibility that can be used as microscale ... proof that "bead-spring" polymers, introduced as theory in the ... as required and should be of interest to materials ... The work led by Rice chemical and biomolecular engineer ...
(Date:7/28/2014)... body,s natural virus killers to prevent and treat HIV ... strong inflammatory response these molecules can arouse as they ... by scientists at the Weizmann Institute and the National ... activity of these molecules interferons around the ... course of the disease. Their research appeared in ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Seeing is bead-lieving 2Interfering with interferon 2
... syndrome has focused on the DYRK1A gene. The superexpression ... to Mr Garikoitz Azkona. In his PhD thesis, ... role of DYRK1A , Mr Azkona argues that this ... that persons with Down,s syndrome have regarding visual-spatial memory. ...
... 2010 2009 estimates projected that in the United States ... and 14,600 women would die of the disease. Often ... and a relatively low 5-year survival rate of about 45%. ... in the March 2010 issue of the Journal of ...
... treatment for cancer might come from fish says a new ... the FASEB Journal ( http://www.fasebj.org ). In the ... or "DHA," and its derivatives in the body kill neuroblastoma ... a wide range of cancers, including neuroblastoma, medulloblastoma, colon, breast, ...
Cached Biology News:DYRK1A gene may be 1 of most influential factors in Down syndrome 2Dietary factors influence ovarian cancer survival rates 2
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
AC input: 230 V...
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
Biology Products: